Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14949214 | 0.91 | KDR (0.49) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL14949223 | 0.91 | KDR (0.49) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL14949208 | 0.90 | KDR (0.46) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL14949218 | 0.90 | KDR (0.46) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL14949644 | 0.88 | KDR (0.44) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL16788759 | 0.88 | KDR (0.55) | KDRPDGFRAFGFR2METTEK | |
| SCHEMBL14949213 | 0.86 | EGFR (0.54) | KDRPDGFRALCKMETEGFR | |
| SCHEMBL14949232 | 0.86 | KDR (0.46) | KDRPDGFRAFGFR2MET | |
| SCHEMBL14949219 | 0.86 | KDR (0.44) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL14949313 | 0.84 | KDR (0.46) | KDRPDGFRAFGFR2LCKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | KDR 533/4885PDGFRA 498/4885FGFR2 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.